T. Parker

发表

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

F. Foss, T. Parker, Lisa Barbarotta, 2013, Future oncology.

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias

M. Dhodapkar, J. Kortmansky, A. Branagan, 2021, Blood Advances.

Management of isolated calf vein thrombosis in cancer patients

T. Sarac, A. Dardik, L. Skrip, 2016, Vascular.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (E1A11): a multicenter, open label, phase 3, randomized, controlled trial

Prashant, P. Richardson, N. Callander, 2020 .

A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma

F. Foss, T. Parker, 2018, The oncologist.

Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Mengyang Di, S. Giri, S. Huntington, 2021, Leukemia & lymphoma.

Clinical and Serologic Responses After a Two‐dose Series of High‐dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single‐arm Trial

M. Dhodapkar, D. Zelterman, R. Albrecht, 2017, Clinical Lymphoma, Myeloma & Leukemia.

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

G. Ahmann, R. Fonseca, S. Jagannath, 2016 .

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

G. Ahmann, R. Fonseca, S. Jagannath, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant

J. Bolognia, D. Cooper, S. Seropian, 2013, Bone Marrow Transplantation.

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.

S. Giri, S. Huntington, N. Neparidze, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.

S. Gore, S. Halene, J. Bewersdorf, 2021, Clinical lymphoma, myeloma & leukemia.

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart.

M. Dhodapkar, T. Parker, Noffar Bar, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2019, The New England journal of medicine.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019, JCI insight.

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019 .

Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy.

M. Dhodapkar, Lin Zhang, K. Dhodapkar, 2017, Blood advances.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

S. Lonial, P. Richardson, Shaji K. Kumar, 2020, The Lancet. Oncology.

Whole-exome sequencing in evaluation of patients with venous thromboembolism.

J. Huntington, Eun-Ju Lee, A. Leavitt, 2017, Blood advances.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

D. Hose, B. Barlogie, N. Munshi, 2018, JCI insight.

Chronic lymphocytic leukemia: prognostic factors and impact on treatment.

M. Strout, T. Parker, Terri L. Parker, 2011, Discovery medicine.

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.

M. Dhodapkar, S. Gettinger, M. Samur, 2020, JCI insight.

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*

Anlong Li, M. Girardi, F. Foss, 2019, Leukemia & lymphoma.

Leukaemic vasculitis with myelodysplastic syndrome

I. Odell, A. Zeidan, O. Colegio, 2015, The Lancet.

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

R. Orlowski, B. Durie, S. Usmani, 2020 .

Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman

R. Nowak, C. Price, T. Parker, 2016, BMJ Case Reports.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Breeze, M. Dimopoulos, R. Vij, 2021, BMC cancer.

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

S. Lonial, P. Richardson, Shaji K. Kumar, 2020, Journal of Clinical Oncology.

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Shah, J. Breeze, M. Dimopoulos, 2020, BMC Cancer.

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

M. Dimopoulos, S. Jagannath, R. Vij, 2018, Blood.